New version of ColonCADT launched at ECR
March 06 2009 - 2:00AM
RNS Non-Regulatory
TIDMMDST
Medicsight Plc
06 March 2009
?
+----------------------------------+-------------------------------------+
| | Friday 6 March 2009 |
+----------------------------------+-------------------------------------+
Medicsight PLC
("Medicsight" or "the Company")
Medicsight unveils new version of ColonCAD(TM) at ECR 2009
Medicsight PLC (AIM:MDST), industry leader in the development of Computer-Aided
Detection (CAD) and image analysis software which assists in the early detection
and diagnosis of disease, is pleased to announce it has launched ColonCAD API
4.0, the latest version of its computer-aided detection software, today at the
European Congress of Radiology (ECR 2009) show in Vienna. The software is
designed to assist radiologists in the detection of colorectal polyps in CT
colonography image data. Version 4.0 includes a significant increase in the
performance of the polyp detection algorithm, reducing the number of false
positive CAD marks displayed for each patient case.
Dr David Burling, Consultant Gastrointestinal Radiologist and VC Program
Director at St. Mark's Hospital, London, UK commented today "We welcome this
latest improvement to Medicsight's ColonCAD product. CAD is now an integral
part of our reading strategy in routine clinical practice. It improves
interpretation accuracy and is complimentary to workflow".
Internal testing on a dataset of 91 patient cases showed that the ColonCAD API
4.0 maintains the same high levels of sensitivity to the previous version but
displays a 50% reduction in false positives, with the CAD now returning a mean
of 6.5 false positive marks per patient case *. ColonCAD API 4.0 demonstrates
the following sensitivity:
+---------------------------+------------------+
| Size of Polyp | Sensitivity |
+---------------------------+------------------+
| 2mm-50mm | 85% |
+---------------------------+------------------+
| 6mm-9mm | 90% |
+---------------------------+------------------+
| 10mm+ (clinically | 92%+ |
| significant) | |
+---------------------------+------------------+
The patient data used in this testing remained independent from the development
of the CAD and have been endoscopically validated and reviewed by a panel of
expert radiologists to determine the ground truth against which the CAD
performance was assessed.
Allan Rowley, Chief Executive of Medicsight, commented "Previous research has
shown Medicsight's ColonCAD significantly improves the performance of
radiologists in the detection of polyps in CT colonography image data. The
reduction in the numbers of false positives returned by our latest version of
CAD is expected to further improve the performance of radiologists, by reducing
the number of CAD marks which must be assessed when reviewing a patient
dataset."
ColonCAD API 4.0 has been CE Marked and will be available for sale in Europe
through Medicsight's network of partners.
More than 17,000 medical and industry professionals from over 95 countries will
be attending this year's ECR which is taking place in the Austria Center, Vienna
from 6-10 March. Visitors will be able to see demonstrations of the Medicsight
ColonCAD software integrated into their partners' 3D advanced visualisation
workstations at the company's exhibition booth no 506 in Expo E.
* Data on file, Medicsight PLC
- ENDS -
For further information:
+-------------------------------------------+----------------------------+
| Medicsight PLC | www.medicsight.com |
+-------------------------------------------+----------------------------+
| Allan Rowley | +44 (0)20 7605 7950 |
+-------------------------------------------+----------------------------+
| Nomura Code | |
+-------------------------------------------+----------------------------+
| Juliet Thompson | +44 (0) 20 7776 1204 |
| Jonathan Senior | +44 (0) 20 7776 1219 |
+-------------------------------------------+----------------------------+
Media enquiries:
+-------------------------------------------+----------------------------+
| Abchurch | +44 (0) 20 7398 7700 |
+-------------------------------------------+----------------------------+
| Heather Salmond / Stephanie Cuthbert / | +44 (0) 20 7398 7718 |
| Simone Alves | |
+-------------------------------------------+----------------------------+
| stephanie.cuthbert@abchurch-group.com | www.abchurch-group.com |
+-------------------------------------------+----------------------------+
Notes to editors
Medicsight PLC is a UK-headquartered, research driven, leading developer of
computer-aided detection (CAD) and image analysis software for the
medical imaging market. The CAD software automatically highlights suspicious
areas on computerised tomography (CT) scans of the colon and lung,
helping radiologists to identify, measure and analyse potential disease and
early indicators of disease. Medicsight's CAD software has been validated using
one of the world's largest and most population diverse databases of verified
patient CT scan data. Medicsight's ColonCAD(TM) and LungCAD(TM) software
products are seamlessly integrated with the advanced 3D visualisation
workstations of several industry-leading imaging equipment partners.
About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware such as
Multi-Detector CT scanners, radiologists are facing a growing challenge in the
amount of detailed patient image data that they must review for each patient
examination. Some CT scan examinations generate as many as 2000 images per
patient. Review of this data by the radiologist is not only time-consuming but
also prone to error due to reader fatigue. CAD software can help the reviewing
radiologist by analysing the image data and automatically highlighting
suspicious regions of interest for closer inspection. Without CAD software some
potential abnormalities or areas of disease may be overlooked. This can
be critical for diagnosis and the management of patient outcomes as early
detection of disease greatly increases the probability of successful treatment
and a positive therapeutic outcome. In addition to supporting individual
radiologists CAD also has the potential to help standardise CT interpretation
across both individuals and institutions thereby supporting population based
screening programmes.
About Medicsight's CAD software
Medicsight's ColonCAD(TM) and LungCAD(TM) software use an advanced CAD algorithm
to analyse CT scans of the colon and lung and automatically highlight suspicious
areas that may be indicators of disease. CAD may highlight areas easily
overlooked by the reviewing radiologist, such as small lesions or regions that
are hidden from view behind folds in the colon or normal structures and
surrounding tissue in the lung.
Both CAD products seamlessly integrate with the advanced 3D visualisation
platforms of industry-leading imaging equipment partners. The integrated systems
provide sophisticated image viewing capabilities, including 3D reconstructed
image data, with the added advantage of demonstrating automatic CAD findings to
assist clinical end users in the detection and analysis of disease. This allows
clinical end users to perform either a 'second read', where CAD findings are
displayed to the user after completion of an initial review of the CT scan data,
or a 'concurrent read' where CAD findings are displayed during the user's
initial review of the original CT scan images.
Since inception, Medicsight has developed close and lasting relationships with
some of the world's foremost clinicians in product related areas. This provides
the Company with a wealth of clinical expertise and dedicated clinical research
to support ongoing product development. Medicsight also collaborates with a
number of leading academic institutions and clinical research programmes
worldwide to develop the Company's comprehensive database of population diverse
verified patient CT scan data, thus allowing Medicsight's products to be
validated to the highest possible standards.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAILFSEVIIEIIA
Medicsight (LSE:MDST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medicsight (LSE:MDST)
Historical Stock Chart
From Jul 2023 to Jul 2024
